We assessed trends in treatment of patients with CRE from 2012 through 2018. We detected decreased utilization of aminoglycosides and colistin and increased utilization in extended-spectrum cephalosporins and ceftazidime-avibactam. We found significant uptake of ceftazidime-avibactam, a newly approved antibiotic, to treat CRE infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466386 | PMC |
| http://dx.doi.org/10.1017/ice.2021.452 | DOI Listing |
Publication Analysis
Top Keywords
newly approved
8
uptake newly
4
approved antibiotics
4
antibiotics prescribed
4
prescribed patients
4
patients carbapenem-resistant
4
carbapenem-resistant enterobacterales
4
enterobacterales cre
4
cre assessed
4
assessed trends
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!